DexCom, Inc. vs Hormel Foods Corp — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Hormel Foods Corp trades at $19.19 (market cap $10.69B). The key difference: DexCom, Inc. is far larger — about 3× Hormel Foods Corp's market cap, and Hormel Foods Corp pays a 6.02% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Hormel Foods Corp for 99 Days on average.
| DXCM | HRL | |
|---|---|---|
Market Cap | $31.86B | $10.69B |
Volume | 3,607,070 | 10,041,387 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $26.50 |
52-Week Low | $54.84 | $19.42 |
Typical Hold Time | 62 Days | 99 Days |
Enterprise Value | $31.32B | $12.67B |
Dividend Yield | — | 6.02% |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Hormel Foods (HRL) trades at $19.42, down 0.66% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 31.32 and net margin of 2.82%, though recent quarters beat EPS estimates. The company's $1.06B Brakebush acquisition aims to expand foodservice presence, while maintaining a 60-year dividend streak. Cash flow trends show improvement from 2025's negative $71M to projected 2026 positive $245M.
HRL presents a value opportunity with 25% upside to consensus target of $24.25, supported by dividend stability. However, declining profit margins and elevated valuation multiples pose headwinds. The Brakebush integration execution and consumer spending trends will be critical for reversing earnings pressure amid competitive food markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →